Please login to the form below

Not currently logged in
Email:
Password:

aflibercep

This page shows the latest aflibercep news and features for those working in and with pharma, biotech and healthcare.

NICE first fast-track appraisal backs Bayer's Eylea

NICE first fast-track appraisal backs Bayer's Eylea

The National Institute for Health and Care Excellence (NICE) has issued its first fast-track guidance, recommending Bayer’s Eylea (aflibercep) in choroidal neovascularisation (CNV).

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics